Intralesional pingyangmycin injection sclerotherapy for oral ranulas

Abstract

Objective: To investigate the efficiency of pingyangmycin (PYM) intralesional injection for the treatment of ranulas in clinical practice. Methods: PYM concentrations were 2.0 mg/ml (8 mg PYM powder + 1 ml normal saline + 2 ml 2% lidocaine + 1 ml dexamethasone). The mixed PYM solution was intralesional injected into ranulas after drawing out isometric cyst fluid in 3 patients. Results: The ranulas of 3 patients showed total disappearance after the sclerotherapy, and no recurrence was found after 6 months to 3 years’ follow-up. Compared to surgical therapy, the PYM sclerotherapy was advocated by clinicians for its advantages of less injury, no scar, less suffering, etc. Conclusions: PYM is an effective sclerosing agent for ranulas. Intracystic injection of PYM may be an optimal method for the treatment of ranulas.

Share and Cite:

Chen, Z. , Zheng, J. and Zhang, S. (2013) Intralesional pingyangmycin injection sclerotherapy for oral ranulas. Open Journal of Stomatology, 3, 359-364. doi: 10.4236/ojst.2013.37061.

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1] Zhang, J., Chen, C. and Zhang, Z. (2003) Intralesional injection of pingyangmycin for hemangiomas and vascular malformations in oral and maxillofacial region: A systematic review of the Chinese literature. China Journal of Oral and Maxillofacial Surgery, 1, 102-105.
[2] Muir, T., Kirsten, M., Fourie, P., et al. (2004) Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatric Surgery International, 19, 766-773.
http://dx.doi.org/10.1007/s00383-003-1058-6
[3] Yang, X.J., Zheng, J.W., Zhou, Q., et al. (2010) Intracystic injection of pingyangmycin (PYM) might be a more favorable option for treatment of oral and plunging ranulas. Shanghai Kou Qiang Yi Xue, 19, 447-448.
[4] de Visscher, J.G., van der Wal, K.G. and de Vogel, P.L. (1989) The plunging ranula. Pathogenesis, diagnosis and management. Journal of Cranio-Maxillofacial Surgery, 17, 182-185.
http://dx.doi.org/10.1016/S1010-5182(89)80020-4
[5] Gilbert, L.D., Bakos, L.H. and Graves, R.W. (1981) Sodium morrhuate—An alternative in the treatment of soft tissue hemangiomas. Review of the literature and case reports. West Virginia Dental Journal, 55, 11-15.
[6] Zhao, J.H., Zhang, W.F. and Zhao, Y.F. (2004) Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate. International Journal of Oral and Maxillofacial Surgery, 33, 463-466.
http://dx.doi.org/10.1016/j.ijom.2003.10.003
[7] He, W., Gu, A.L. and Shang, J.L. (2007) Comparison of the clinical therapeutic effects between local injection of pingyangmycin and sodium morrhuate on oral and maxillofacial venous malformation. Zhonghua Kou Qiang Yi Xue Za Zhi, 42, 308-309.
[8] Rho, M.H., Kim, D.W., Kwon, J.S., et al. (2006) OK-432 sclerotherapy of plunging ranula in 21 patients: It can be a substitute for surgery. American Journal of Neuroradiology, 27, 1090-1095.
[9] Patel, M.R., Deal, A.M. and Shockley, WW. (2009) Oral and plunging ranulas: What is the most effective treatment? Laryngoscope, 119, 1501-1509.
http://dx.doi.org/10.1002/lary.20291
[10] Blonski, W.C., Campbell, M.S., Faust, T., et al. (2006) Successful aspiration and ethanol sclerosis of a large, symptomatic, simple liver cyst: Case presentation and review of the literature. World Journal of Gastroenterology, 12, 2949-2954.
[11] Kim, K.H., Sung, M.W., Roh, J.L., et al. (2004) Sclerotherapy for congenital lesions in the head and neck. Otolaryngology—Head and Neck Surgery, 131, 307-316.
http://dx.doi.org/10.1016/j.otohns.2004.02.018
[12] Ogita, S., Tsuto, T., Nakamura, K., et al. (1994) OK-432 therapy in 64 patients with lymphangioma. Journal of Pediatric Surgery, 29, 784-785.
http://dx.doi.org/10.1016/0022-3468(94)90370-0
[13] Brewis, C., Pracy, J.P. and Albert, D.M. (2000) Treatment of lymphangiomas of the head and neck in children by intralesional injection of OK-432 (picibanil). Clinical Otolaryngology, 25, 130-134.
http://dx.doi.org/10.1046/j.1365-2273.2000.00338.x
[14] Sung, M.W., Lee, D.W., Kim, D.Y., et al. (2001) Sclerotherpy with picibanil (OK-432) for congenital lymphatic malformation in the head and neck. Laryngoscope, 111, 1430-1433.
http://dx.doi.org/10.1097/00005537-200108000-00020
[15] Bloom, D.C., Perkins, J.A. and Manning, S.C. (2004) Management of lymphatic malformations. Current Opinion in Otolaryngology & Head and Neck Surgery, 12, 500-504.
http://dx.doi.org/10.1097/01.moo.0000143971.19992.2d
[16] Kim, M.G., Kim, S.G., Lee, J.H., et al. (2008) The therapeutic effect of OK-432 (picibanil) sclerotherapy for benign neck cysts. Laryngoscope, 118, 2177-2181.
http://dx.doi.org/10.1097/MLG.0b013e3181864acf
[17] Zhi, K., Wen, Y., Li, L., et al. (2008) The role of intralesional Pingyangmycin in the treatment of venous malformation of facial and maxillary region. International Journal of Pediatric Otorhinolaryngology, 72, 593-597.
http://dx.doi.org/10.1016/j.ijporl.2008.01.007
[18] Zhao, S.F., Shou, W.D., Hu, Q.G., et al. (2010) Treatment of sublingual cyst with intracystic injection of Pinyangmycin: Clinical results in 785 consecutive cases. China Journal of Oral and Maxillofacial Surgery, 8, 47-49.
[19] Zhou, Q., Zheng, J.W., Yang, X.J., et al. (2010) Concentration is more important than dose when using intralesional Pingyangmycin injection for treatment of vascular malformations. Shanghai Kou Qiang Yi Xue, 19, 220-221.
[20] Sung, M.W., Chang, S.O., Choi, J.H., et al. (1995) Bleomycin sclerotherapy in patients with congenital lymphatic malformation in the head and neck. American Journal of Otolaryngology, 16, 236-241.
http://dx.doi.org/10.1016/0196-0709(95)90149-3
[21] Praetorius, F. and Hammarstrom, L. (1992) A new concept of the pathogenesis of oral mucous cysts based on a study of 200 cases. The Journal of the Dental Association of South Africa, 47, 226-231.

Copyright © 2024 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.